BioMedomics
BioMedomics, a Morrisville, NC-based point-of-care diagnostics company, develops lateral flow immunoassay tests for sickle cell disease, fungal infections, and women's health, distributed through partners in 40+ countries. Acquired by OraSure Technologies in November 2025.
- Company typePrivate
- Founded2007
- HeadquartersMorrisville, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What BioMedomics does
BioMedomics is a privately-held point-of-care diagnostics company headquartered in Morrisville, North Carolina, founded in 2006-2007. The company develops lateral flow immunoassay (LFIA)-based rapid diagnostic tests for clinical and field settings without centralized laboratory infrastructure, with a primary focus on sickle cell disease (SCD) screening in resource-limited regions of Sub-Saharan Africa, the Middle East, and South Asia. Its operations are housed in a 15,000-square-foot ISO 13485-compliant research and manufacturing facility in the Research Triangle Park area.
The company's product portfolio is anchored by Sickle SCAN and Sickle SCAN-EZ — multiplexed, qualitative point-of-care immunoassays that simultaneously detect hemoglobins A, S, and C, enabling clinicians to distinguish normal, carrier, and sickle cell disease samples in 5 minutes with combined sensitivity and specificity exceeding 99% (validated against hemoglobin electrophoresis). Sickle SCAN uses a 5 µL fingerstick blood sample in cassette format, while Sickle SCAN-EZ is a 2 µL strip format designed for high-volume public-health screening at a lower per-test price. Adjacent products include Fungi SCAN (an all-in-one fluorescent KOH fungal staining reagent), Femi SCAN (a dual fluorescence staining agent for vaginal infections), and previously SARS-CoV-2 antigen and COVID-19 IgM-IgG antibody rapid tests. The company claims to be the world's leading manufacturer of hemoglobin subtype antibodies (A, C, E, F, S), supporting an intellectual property portfolio of 15 granted patents with 13 additional applications pending, backed by over $25 million in cumulative R&D investment.
BioMedomics operates a capital-light, channel-driven commercial model, selling through authorized distribution partners in more than 40 countries including Helena Laboratories (Australia), Laborex Tanzania (Tanzania), and Assene-Laborex (Nigeria). Pricing is quote-based with no publicly disclosed list rates; prospective buyers are routed through a Request Quote form and direct sales contact. The company supplements partner-channel sales with grant-funded screening initiatives — most notably a 3-year Sickle Cell Disease Independent Research Grant program in Sub-Saharan Africa launched in June 2024 — and with event-driven awareness campaigns in partnership with healthcare providers, NGOs, and patient brand ambassadors. The company is ISO 13485:2016 certified by BSI Group of America and holds regional approvals including CE mark, Saudi FDA, Australian TGA, and Tanzania TMDA. None of BioMedomics' products are currently approved for in vitro diagnostic use in the United States. In November 2025, BioMedomics was acquired by OraSure Technologies (NASDAQ: OSUR) for approximately $4 million, becoming a wholly-owned subsidiary focused on expanding sickle cell disease testing into Africa and Latin America.
BioMedomics firmographics
Firmographics- Name
- BioMedomics
- Legal name
- BioMedomics, Inc.
- Website
- https://biomedomics.com
- Company type
- Private
- Founded year
- 2007
- Operating status
- Acquired
- Headcount range
- 11–50 employees
- Short description
- BioMedomics, a Morrisville, NC-based point-of-care diagnostics company, develops lateral flow immunoassay tests for sickle cell disease, fungal infections, and women's health, distributed through partners in 40+ countries. Acquired by OraSure Technologies in November 2025.
- Ownership category
- akta.pro rank
Where BioMedomics is headquartered
LocationHeadquarters
- HQ city
- Morrisville
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
BioMedomics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Operations, Personnel, Supply Chain, Marketing or Sales
Revenue model
- Point-of-Care Diagnostic Product Sales: BioMedomics generates revenue through the direct sale of its point-of-care diagnostic test kits, including Sickle SCAN, Sickle SCAN-EZ, Fungi SCAN, Femi SCAN, and previously the SARS-CoV-2 Antigen Test and COVID-19 IgM-IgG Antibody Rapid Test. Products are sold through distribution partners in over 40 countries. As a commercial-stage company acquired by OraSure Technologies in November 2025, revenue is derived from product shipments to distributors and healthcare institutions.
- Sickle Cell Disease Grant Programs: BioMedomics operates a grants program providing Sickle SCAN test kits (100-200 tests per project) to NGOs, clinics, and hospitals in Sub-Saharan Africa for advancing sickle cell disease testing and awareness. This program supports market development, customer acquisition, and health outcomes in under-resourced regions, indirectly contributing to long-term revenue growth through market penetration.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Quote-based pricing for Sickle SCAN and other diagnostic products |
Go-to-market motion2 records
Distribution channels2 records
Marketing channels7 records
BioMedomics product offering
Product offeringCore offering
BioMedomics develops, manufactures, and sells rapid point-of-care diagnostic test kits and staining reagents built on proprietary lateral flow immunoassay and fluorescence-based detection technologies. Its commercial portfolio includes Sickle SCAN and Sickle SCAN-EZ for sickle cell disease screening, Fungi SCAN for fungal infection staining, and Femi SCAN for vaginal infection diagnosis, distributed globally through a network of authorized partners.
Product overview
BioMedomics is a point-of-care diagnostic company offering a portfolio of rapid tests and staining reagents. The core products include Sickle SCAN and Sickle SCAN EZ (lateral flow immunoassays for sickle cell disease diagnosis), Fungi SCAN (all-in-one fungal staining reagent), Femi SCAN (dual fluorescence staining agent for vaginal infections), and COVID-19 tests (SARS-CoV-2 Antigen Test Kit and COVID-19 IgM-IgG Antibody Rapid Test). All products are designed for point-of-care use without need for specialized equipment, delivering laboratory-quality results in minutes. The company was acquired by OraSure Technologies in November 2025.
Differentiator
Problem solved
Functional benefit
Brands
- Sickle SCAN: Multiplexed, qualitative, point-of-care immunoassay for rapid diagnosis of sickle cell disorders. Detects hemoglobins A, S, and C to distinguish between normal, carrier, and sickle cell disease samples. Results in 5 minutes with >99% sensitivity and specificity.
- Sickle SCAN-EZ
- Fungi SCAN
- Femi SCAN
Products and services
- Sickle SCAN Multiplexed, qualitative point-of-care immunoassay that detects hemoglobins A, S, and C from a 5 µL whole-blood sample (fingerstick, heelstick, or venipuncture) to distinguish normal, carrier, and sickle cell disease samples, delivering >99% sensitivity/specificity results in 5 minutes for hospitals, clinics, blood banks, and public health programs.
- Sickle SCAN-EZ Strip-format variant of the Sickle SCAN multiplexed hemoglobin A/S/C immunoassay designed for high-volume bulk screening using 2 µL of blood, delivering >99% sensitivity/specificity results in 5 minutes at a lower price point than the cassette format for public health initiatives, community screening events, and laboratories.
- Fungi SCAN All-in-one fungal staining reagent that combines potassium hydroxide (KOH) with a fluorescent compound binding to β-polysaccharides in fungal cell walls plus a counterstain, enabling rapid detection of fungal infections in skin, nail, or hair samples in under 5 minutes using fluorescence microscopy, for dermatologists, infectious disease specialists, and clinical microbiology laboratories.
- Femi SCAN Dual fluorescence staining agent using Sybr Green I and PerCP dyes to stain DNA/RNA of cells and microorganisms in vaginal secretion samples, displaying different colors under fluorescent microscopes to differentiate bacterial, fungal, and parasitic vaginal infections in approximately 2 minutes, with an optional automated slide staining system, for OB/GYN clinics and women's health laboratories.
- SARS-CoV-2 Antigen Test Kit (LFIA) CE approved lateral flow immunoassay detecting SARS-CoV-2 nucleocapsid protein antigen via double-antibody sandwich assay, delivering results in 15-20 minutes for healthcare providers and public health screening, approved by Saudi FDA.
- COVID-19 IgM-IgG Antibody Rapid Test CE approved rapid point-of-care test detecting early (IgM) and late (IgG) COVID-19 antibodies, delivering results in 10 minutes from finger-prick capillary blood, venous whole blood, serum, or plasma samples for healthcare providers and public health programs; Saudi FDA approved.
Quantifiable outcome
- Sickle SCAN achieves >99% sensitivity and specificity vs. hemoglobin electrophoresis, validated in multiple peer-reviewed clinical studies including the DREPATEST study in West Africa and Kanter et al. (2015) in BMC Medicine.
- +3 more outcomes
Companies that use BioMedomics
Customer profileNamed customers3 records
Segments5 records
Ideal customer profiles4 records
BioMedomics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
BioMedomics partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core and minor.
- OraSure Technologies, Inc.coreOraSure Technologies acquired BioMedomics in November 2025 for approximately $4 million. The acquisition was designed to expand OraSure's sickle cell disease testing portfolio with particular focus on high-prevalence markets in Africa and Latin America. As a wholly-owned subsidiary of OraSure, BioMedomics benefits from OraSure's decades-long expertise in scaling life-saving diagnostics worldwide, including its global distribution channels, regulatory expertise (OraSure has two FDA submissions under review), and manufacturing capabilities. The acquisition was described as amplifying BioMedomics' mission by combining breakthrough sickle cell solutions with OraSure's proven track record in infectious disease testing.
- Sub-Saharan African NGOs, Clinics, and Hospitals (via Grant Program)minorBioMedomics launched a 3-year Independent Research Grant program starting June 19, 2024 (World Sickle Cell Day) providing Sickle SCAN test kits to NGOs, clinics, and hospitals in Sub-Saharan Africa. The program aims to increase SCD awareness, improve diagnosis and management, and support educational programs. Maximum grant is 100-200 tests per project over 3-6 month project durations. This initiative advances both social impact and market development objectives.
- Helena Laboratories Australia Pty LtdcoreBioMedomics partnered with Helena Laboratories Australia Pty Ltd to assist with distributing Sickle SCAN to customers in Australia following TGA (Therapeutic Goods Administration) regulatory approval in September 2020.
- Laborex Tanzania LimitedcoreBioMedomics partnered with Laborex Tanzania Limited to assist with distributing Sickle SCAN in Tanzania following approval by the Tanzania Medicines and Medical Devices Authority in September 2020.
- Assene-LaborexcoreBioMedomics distribution partner in Nigeria, Assene-Laborex helped organize and sponsor free sickle cell screening events held during the MEA Rugby League Championship tournament in October 2019. Assene-Laborex continues to serve as BioMedomics' primary distribution partner for the Nigerian market.
- EuracareminorEuracare, a leading Nigerian healthcare provider, partnered with BioMedomics during the MEA Rugby Championship screening events, providing clinical experts to conduct sickle cell tests. The collaboration provided clinical expertise for community-based screening, demonstrating the product's ease of use in real-world healthcare settings.
- Nigeria Rugby League Association (NRLA) / Ade AdebisiminorFormer Nigerian rugby player Ade Adebisi, who has sickle cell disease, was appointed as a brand ambassador for Sickle SCAN. Adebisi, also Vice Chairman and General Manager of the Nigeria Rugby League Association, serves as a patient advocate and public champion for sickle cell awareness and testing. His involvement generates grassroots awareness and lends credibility among affected communities.
Scale indicators8 records
Recent moves7 records
Expansion highlights6 records
BioMedomics competitors and assessment
Company assessmentDirect peers
- Hemex Health: Hemex Health develops the Gazelle POC hemoglobin electrophoresis diagnostic and the HemoTypeSC sickle cell trait/disease test — direct competitors in the rapid POC hemoglobin and sickle cell screening category that BioMedomics targets with Sickle SCAN.
- EKF Diagnostics: EKF Diagnostics develops POC hemoglobin and hematology analyzers (including sickle cell screening products such as the Sickle-Chex control program and point-of-care Hemo Control device), competing directly with BioMedomics in rapid hemoglobin diagnostics.
- Trinity Biotech: Trinity Biotech specializes in clinical diagnostics including hemoglobin disorder and sickle cell testing (Ultra2, HbA1c platforms), positioning it as a direct competitor in the laboratory and point-of-care hemoglobin diagnostic segment.
Broad incumbents
- QuidelOrtho: QuidelOrtho is a large diagnostics incumbent with a broad portfolio of rapid immunoassay and POC tests across infectious disease, women's health, and specialty diagnostics — overlapping category presence with BioMedomics' lateral flow POC product family.
- Abbott Diagnostics: Abbott operates a global POC diagnostics franchise (i-STAT, Afinion, Binax) spanning immunoassays and hematology-relevant tests. It is a broad incumbent competing in POC diagnostics where BioMedomics also plays, with materially greater scale and distribution.
- Sekisui Diagnostics: Sekisui Diagnostics is an established IVD manufacturer with rapid test platforms in infectious disease and hematology adjacent to BioMedomics' lateral flow portfolio, with broader geographic reach and larger commercial scale.
- Bio-Rad Laboratories: Bio-Rad is a diversified life science and clinical diagnostics company with a hematology diagnostics portfolio (including sickle cell testing reagents and Variant II HPLC systems) — a broad incumbent addressing the same hemoglobin disorder workflow as BioMedomics.
- OraSure Technologies: OraSure Technologies is BioMedomics' parent company following the November 2025 acquisition; it is a broader POC diagnostics incumbent with established infectious disease, substance abuse, and oral fluid testing platforms that overlap the POC lateral flow category BioMedomics serves.
- Siemens Healthineers: Siemens Healthineers operates a broad POC and central laboratory diagnostics portfolio (DCA Vantage, ADVIA hematology) that overlaps with BioMedomics' hemoglobin and hematology POC testing value proposition at much greater scale.
Others
- Helena Laboratories: Helena Laboratories is BioMedomics' authorized distribution partner in Australia and a broader clinical diagnostics and electrophoresis equipment supplier — an ecosystem participant rather than a direct competitor.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key highlights7 records
Customer concentration
BioMedomics social profiles
Digital presenceBioMedomics compliance and trust
Trust signalCompliance5 records
BioMedomics financial estimates
Financial estimateRevenue estimate
Valuation estimate
BioMedomics leadership team
Management profileNumber of profiles
Profiles2 records
BioMedomics funding detail
Funding detailFunding overview
Funding rounds5 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
BioMedomics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about BioMedomics
What does BioMedomics do?
BioMedomics develops, manufactures, and sells rapid point-of-care diagnostic test kits and staining reagents built on proprietary lateral flow immunoassay and fluorescence-based detection technologies. Its commercial portfolio includes Sickle SCAN and Sickle SCAN-EZ for sickle cell disease screening, Fungi SCAN for fungal infection staining, and Femi SCAN for vaginal infection diagnosis, distributed globally through a network of authorized partners.
Is BioMedomics a public or private company?
BioMedomics is a private company. It is classified as corporate owned and is currently acquired.
When was BioMedomics founded?
BioMedomics was founded in 2007. It employs 11 to 50 people.
Where is BioMedomics based?
BioMedomics is headquartered in Morrisville, United States, in the North America region.
How does BioMedomics make money?
Two revenue lines are on record. Point-of-Care Diagnostic Product Sales are the primary driver. The others are sickle Cell Disease Grant Programs.
Who are BioMedomics's main competitors?
Direct peers on record are Hemex Health, EKF Diagnostics and Trinity Biotech. Broad incumbents are QuidelOrtho, Abbott Diagnostics, Sekisui Diagnostics, Bio-Rad Laboratories, OraSure Technologies and Siemens Healthineers. Helena Laboratories is listed as an others.
Does BioMedomics have an API?
No public API is recorded for BioMedomics.